Genomic Remodeling
Type Mechanism / biological process
Primary compound GHK-Cu
Overview
Genomic remodeling refers to compounds that broadly reprogram gene expression rather than activating a single receptor. The paradigm case is GHK-Cu, which at physiological concentrations (1 nM–1 μM) alters expression of 4,000+ distinct genes — 31.2% of the human genome.
This is categorically different from receptor agonism: no single receptor mediates these effects. The peptide acts as a tissue remodeling signal that cells interpret and act upon through their own regulatory networks.
GHK-Cu’s Genomic Reach
Broad Institute cMap data (2010–2014): 1 nM–1 μM GHK-Cu:
| Direction | % of altered genes | Pattern |
|---|---|---|
| Upregulated | 59% | Repair, antioxidant, DNA maintenance, collagen, elastin |
| Downregulated | 41% | Inflammation, senescence, cancer progression |
Key Upregulated Gene Sets
| Gene set | Change | Functional outcome |
|---|---|---|
| COL1A1, COL3A1, COL4A1 | Strong | Fibrillar + basement membrane collagen |
| Elastin, Fibronectin, Laminin | Strong | ECM elasticity and integrity |
| Decorin, Chondroitin sulfate | Strong | Organized fibrillogenesis (prevents keloids) |
| SOD1/2, Catalase, GPX1 | +45–131% | Endogenous antioxidant defense |
| Complex I–V (ETC genes) | +45–218% | Mitochondrial biogenesis |
| OGG1, RAD50 | +102–175% | DNA repair (base excision + DSB) |
| 6/12 caspase genes | Upregulated | Apoptosis in aberrant cells |
Key Downregulated Gene Sets
| Gene set | Functional outcome |
|---|---|
| NF-κB (p65) | Blocked nuclear translocation — halts inflammaging |
| TNF-α, IL-6, IL17A | Tissue degradation arrest |
| FAK-paxillin complex | Anti-metastatic |
SIRT1 — The Central Epigenetic Enzyme
GHK-Cu directly binds and activates SIRT1 (confirmed via molecular docking at Glu230 + Asn226, 2023–2025):
- SIRT1 deacetylates downstream targets
- Suppresses STAT3 → anti-inflammatory
- Activates PGC-1α → mitochondrial biogenesis
Comparison to NAD+ precursors (NMN/NR):
- NMN/NR → provide NAD+ substrate for SIRT1
- GHK-Cu → increases SIRT1 enzyme expression and activity itself
- Combined = synergistic (substrate + enzyme both optimized)
Anti-Cancer Profile
Critical distinction from growth-factor approaches:
| Effect | Mechanism | |
|---|---|---|
| FAK-paxillin | Downregulated | Blocks cancer cell migration/metastasis |
| Caspase genes | Upregulated | Forces apoptosis in aberrant cells |
| Proliferative signaling | Downregulated in cancer networks | Reduces oncogenic drive |
GHK-Cu is pro-proliferative for healthy fibroblasts, anti-proliferative for neoplastic cells — a genuinely smart signal.
Comparison to Other Genomic Modulators
| Compound | Mechanism | Genomic breadth |
|---|---|---|
| GHK-Cu | Matrikine / copper chaperone | 31.2% of genome |
| Resveratrol | SIRT1 activator (indirect) | Narrower |
| Rapamycin | mTOR inhibition | Narrower |
| Retatrutide | Receptor agonist (GLP-1/GIP/GCGR) | Single pathway per receptor |
Links
- GHK-Cu (primary compound)
- Tissue Repair (ECM remodeling overlap)
- Peptides MOC
- Sirtuins and NAD+ (note pending — GHK-Cu’s NAD+-dependent sirtuin activation is related to NMN NAD+ mechanisms)
Source: Broad Institute cMap · Campbell et al. COPD reversal (2012) · GHK-Cu SIRT1 docking studies (2023–2025) · PeptideDosages.com 2026-03-20